Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Iwama, 2014, Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in rearrangement-positive lung cancer, Onco Targets Ther, 7, 375 Bang, 2011, The potential for crizotinib in non-small cell lung cancer: a perspective review, Ther Adv Med Oncol, 3, 279, 10.1177/1758834011419002 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Scagliotti, 2012, ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development, Eur J Cancer, 48, 961, 10.1016/j.ejca.2012.02.001 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2016, Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, 34, 2858, 10.1200/JCO.2015.63.5888 Solomon, 2014, Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st-line crizotinib vs pemetrexed-platinum chemotherapy (PPC) in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC), Ann Oncol, 25, iv427, 10.1093/annonc/mdu349.4 Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906 Shaw, 2015, Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer, Clin Adv Hematol Oncol, 13, 282 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316 Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539 Rolfo, 2014, ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it, Transl Lung Cancer Res, 3, 250 Awad, 2014, ALK inhibitors in non-small cell lung cancer: crizotinib and beyond, Clin Adv Hematol Oncol, 12, 429 Kim, 2016, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, 17, 452, 10.1016/S1470-2045(15)00614-2 Friboulet, 2014, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov, 4, 662, 10.1158/2159-8290.CD-13-0846 Crinò, 2016, Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, 34, 2866, 10.1200/JCO.2015.65.5936 Li, 2014, Ceritinib (LDK378) overcomes crizotinib resistance in NSCLC, Cancer Res, 74 Li, 2015, Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer, Clin Lung Cancer, 16, 86, 10.1016/j.cllc.2014.09.011 Brookmeyer, 1982, A confidence interval for the median survival time, Biometrics, 38, 29, 10.2307/2530286 Camidge, 2011, Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed, J Thorac Oncol, 6, 774, 10.1097/JTO.0b013e31820cf053 Lee, 2011, Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer, J Thorac Oncol, 6, 1474, 10.1097/JTO.0b013e3182208fc2 Shaw, 2011, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, Lancet Oncol, 12, 1004, 10.1016/S1470-2045(11)70232-7 Nokihara, 2016, Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study, Proc Am Soc Clin Oncol, 34 Gettinger, 2016, Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial, Lancet Oncol, 17, 1683, 10.1016/S1470-2045(16)30392-8 Dziadziuszko, 2017, Phase 1 study of ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in ALK+ metastatic NSCLC, J Thorac Oncol, 12, S1184, 10.1016/j.jtho.2016.11.1666 Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, 10.1016/S0140-6736(17)30565-2